\

Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need

Press Releases

Get News Alerts by Email

Sep 17, 2020

Cardiff Oncology Presents Data at ESMO Confirming Efficacy of Onvansertib and Durability of Response in KRAS-Mutated Metastatic Colorectal Cancer (mCRC)

-10 of 11 (91%) patients achieved disease control (SD - stable disease plus PR - partial response) with only 1 patient progressing in <6 months while on treatment
Sep 15, 2020

Cardiff Oncology to Host Key Opinion Leader Call Discussing KRAS-Mutated Colorectal Cancer and Highlighting Data from Onvansertib Phase 1b/2 Trial

- Virtual event will take place on Wednesday, Sept. 23, 2020 at 11 a.m. EDT and will include a Q&A session
Sep 14, 2020

Cardiff Oncology to Present Data Further Demonstrating the Safety and Efficacy of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer Patients
Aug 11, 2020

Cardiff Oncology Announces Second Quarter 2020 Results and Highlights
Aug 4, 2020

Cardiff Oncology to Participate in Fireside Chat at the Virtual BTIG Biotechnology Conference

- Fireside chat will address KRAS inhibition and the promise of onvansertib as a new therapeutic option in colorectal cancer

Show per page